Sanofi India Limited has released its financial results for the quarter ended March 31, 2026, highlighting strong performance in its insulin portfolio. The company reported a revenue of ₹4,723 million and a profit of ₹1,026 million for the quarter. Additionally, the Board of Directors has announced leadership transitions, including the appointment of Mr. Rahul Bhatnagar as the Chairman of the Board, effective April 30, 2026.
Financial Highlights for the Quarter
Sanofi India delivered a strong performance during the quarter ended March 31, 2026. The company achieved a revenue from operations of ₹4,723 million, compared to ₹4,198 million in the previous quarter. The profit for the period stood at ₹1,026 million. The insulin portfolio was a primary growth driver, achieving double-digit growth and demonstrating the company’s established position in the diabetes injectable segment.
Strategic Focus and Market Outlook
Despite the competitive landscape, the company continues to see growth in its core segments, including Cardiovascular, Oral anti-Diabetes, and the Central Nervous System. The company’s leadership highlighted a 14% registered growth vs the previous quarter and 19% registered growth vs last year, emphasizing the essential role of insulin in comprehensive diabetes care. The company remains focused on operational excellence and expanding access to both established and innovative therapies throughout India.
Leadership Transitions
The company announced significant changes to its Board of Directors. The tenure of Independent Directors Mr. Aditya Narayan and Mrs. Usha Thorat will conclude at the close of business hours on April 29, 2026. Following these departures, the Board has appointed Mr. Rahul Bhatnagar as the new Chairman of the Board, effective April 30, 2026. Furthermore, the company has completed a re-constitution of its key committees, including the Audit, Nomination and Remuneration, Stakeholders Relationship, Risk Management, and Corporate Social Responsibility committees.
Source: BSE
